When did Emergent Biosolutions report Q4 2024 earnings?

Emergent Biosolutions (EBS) reported Q4 2024 earnings on March 3, 2025 after market close.

What were Emergent Biosolutions's Q4 2024 revenue and EPS?

Emergent Biosolutions reported revenue of $189.3M and eps of $0.05 for Q4 2024.

Did Emergent Biosolutions beat estimates in Q4 2024?

Revenue missed the consensus estimate of $279.0M by $89.7M. EPS beat the consensus estimate of $-0.35 by $0.40.

Where can I find Emergent Biosolutions's Q4 2024 SEC filings?

You can read the 10-K periodic report (0001367644-25-000021) directly on SEC EDGAR. The filing index links above go to sec.gov.

Emergent Biosolutions EBS Q4 2024 Annual earnings

Reported March 3, 2025 · After market close

Revenue$189.3MMiss by $89.7M

EPS$0.05Beat by $0.40

Revenue estimate$279.0M

EPS estimate-$0.35

Next report

Aug 5, 2026 (In 6 days)

Revenue estimate$177.5M

EPS estimate-$0.09

Financials

Q4 2024

Income statement

See full

Revenue$194.7M-29.6%

Gross profit$76.7M-16.2%

Operating income-$9.5M+78.3%

Net income-$31.3M+36.8%

EPS (diluted)-$0.57+35.2%

Balance sheet

See full

Cash & equivalents$105.6M-5.5%

Total debt$676.1M-23.0%

Total equity$482.8M-25.6%

Total assets$1.4B-23.8%

Cash flow

See full

CapEx$1.7M-85.1%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$518M+316%

Enterprise value$1.09B+22.3%

P/S0.5×+0.4×

Profitability

See full

Gross margin34.7%+1.9pp

Operating margin-10.4%-4.8pp

Net margin-18.3%-7.8pp

Returns & leverage

See full

Return on equity-33.7%-11.9pp

Debt / equity1.4×0.0×

Current ratio3.7×+2.6×

Segments

By segment

See full

MCM Products$116.8M-15.4%

Commercial Products$65.1M-41.4%

By product

See full

MCM Product sales$116.8M-15.4%

Commercial Product sales$65.1M-41.4%

Versus estimates

Revenue

Q1 2026$156.1MBeat by $11.1M Q4 2025$148.7MMiss by $68.8M Q3 2025$231.1MBeat by $13.6M Q2 2025$140.9MMiss by $62.8M Q1 2025$222.2MBeat by $3.2M

Q4 2024$189.3MMiss by $89.7M

Diluted EPS

Q1 2026$0.21Beat by $0.46 Q4 2025-$0.43Miss by $0.54 Q3 2025$1.06Beat by $1.18 Q2 2025$0.16Beat by $0.42 Q1 2025$0.71Beat by $0.22

Q4 2024$0.05Beat by $0.40

Ask the moment Emergent Biosolutions reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Emergent Biosolutions report Q4 2024 earnings?: Emergent Biosolutions (EBS) reported Q4 2024 earnings on March 3, 2025 after market close.
What were Emergent Biosolutions's Q4 2024 revenue and EPS?: Emergent Biosolutions reported revenue of $189.3M and eps of $0.05 for Q4 2024.
Did Emergent Biosolutions beat estimates in Q4 2024?: Revenue missed the consensus estimate of $279.0M by $89.7M. EPS beat the consensus estimate of $-0.35 by $0.40.
Where can I find Emergent Biosolutions's Q4 2024 SEC filings?: You can read the 10-K periodic report (0001367644-25-000021) directly on SEC EDGAR. The filing index links above go to sec.gov.